Free Trial

Cytokinetics (CYTK) News Today

$47.73
-0.48 (-1.00%)
(As of 11:51 AM ET)
Truist Financial Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $70.00
Truist Financial decreased their price objective on Cytokinetics from $86.00 to $70.00 and set a "buy" rating for the company in a report on Wednesday.
JMP Securities Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $78.00
JMP Securities cut their price objective on shares of Cytokinetics from $106.00 to $78.00 and set a "market outperform" rating on the stock in a research report on Tuesday.
Norges Bank Acquires Shares of 722,229 Cytokinetics, Incorporated (NASDAQ:CYTK)
Norges Bank acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 722,229 shares of the biopharmaceutical company's stock, valued
HC Wainwright Weighs in on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK)
Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2024 earnings per share estimates for shares of Cytokinetics in a research report issued on Thursday, May 23rd. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical
Franklin Resources Inc. Reduces Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)
Franklin Resources Inc. lowered its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 41.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 660,682 shares of the biopharmace
Cytokinetics Decides To Go It Alone
Leerink Partnrs Comments on Cytokinetics, Incorporated's FY2027 Earnings (NASDAQ:CYTK)
Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Analysts at Leerink Partnrs cut their FY2027 earnings per share (EPS) estimates for Cytokinetics in a research note issued on Wednesday, May 22nd. Leerink Partnrs analyst R. Ruiz now forecasts that the biopharmaceutical company will earn $3
Cytokinetics (NASDAQ:CYTK) Price Target Lowered to $60.00 at Bank of America
Bank of America cut their target price on shares of Cytokinetics from $70.00 to $60.00 and set a "neutral" rating for the company in a research report on Thursday.
Cytokinetics (NASDAQ:CYTK) Shares Gap Down After Analyst Downgrade
Cytokinetics (NASDAQ:CYTK) Shares Gap Down Following Analyst Downgrade
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen analysts that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the com
Trexquant Investment LP Increases Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)
Trexquant Investment LP grew its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 411.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 109,810 shares of the biopharmaceutical company's stock after buying an additional 88,342 shares during the
Bridger Management LLC Makes New $1.88 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)
Bridger Management LLC bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 22,510 shares of the biopharmaceutical company's stock, valued at ap
Cytokinetics to Host Muscle Seminar
Charles Schwab Investment Management Inc. Has $65.96 Million Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)
Charles Schwab Investment Management Inc. boosted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 789,969 sha
Thornburg Investment Management Inc. Lowers Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)
Thornburg Investment Management Inc. lessened its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 21.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 85,199 shares of the bio
Jefferies Keeps Their Buy Rating on Cytokinetics (CYTK)
Cytokinetics (NASDAQ:CYTK) Receives Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $94.00 target price on shares of Cytokinetics in a report on Tuesday.
Cytokinetics (NASDAQ:CYTK) Shares Down 5.6%
Cytokinetics (NASDAQ:CYTK) Trading Down 5.6%
Get Cytokinetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

The #1 Crypto for AI (Ad)

We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”

Learn more about it by watching THIS NOW.

CYTK Media Mentions By Week

CYTK Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CYTK
News Sentiment

0.23

0.78

Average
Medical
News Sentiment

CYTK News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CYTK Articles
This Week

46

8

CYTK Articles
Average Week

Get Cytokinetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CYTK) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners